JP5546532B2 - 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用 - Google Patents

非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用 Download PDF

Info

Publication number
JP5546532B2
JP5546532B2 JP2011508521A JP2011508521A JP5546532B2 JP 5546532 B2 JP5546532 B2 JP 5546532B2 JP 2011508521 A JP2011508521 A JP 2011508521A JP 2011508521 A JP2011508521 A JP 2011508521A JP 5546532 B2 JP5546532 B2 JP 5546532B2
Authority
JP
Japan
Prior art keywords
nanoparticles
zein
prolamin
phospholipid
phase solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011508521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519932A5 (enExample
JP2011519932A (ja
Inventor
ピー． ペルマル，オマタヌー
ケー． ポダラーラ，サティーシュ
エス． カウシィク，ラディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South Dakota State University
Original Assignee
South Dakota State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South Dakota State University filed Critical South Dakota State University
Publication of JP2011519932A publication Critical patent/JP2011519932A/ja
Publication of JP2011519932A5 publication Critical patent/JP2011519932A5/ja
Application granted granted Critical
Publication of JP5546532B2 publication Critical patent/JP5546532B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011508521A 2008-05-09 2009-05-11 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用 Active JP5546532B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12713408P 2008-05-09 2008-05-09
US61/127,134 2008-05-09
PCT/US2009/002935 WO2009137112A1 (en) 2008-05-09 2009-05-11 Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014099344A Division JP5851550B2 (ja) 2008-05-09 2014-05-13 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用

Publications (3)

Publication Number Publication Date
JP2011519932A JP2011519932A (ja) 2011-07-14
JP2011519932A5 JP2011519932A5 (enExample) 2012-06-28
JP5546532B2 true JP5546532B2 (ja) 2014-07-09

Family

ID=41264904

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011508521A Active JP5546532B2 (ja) 2008-05-09 2009-05-11 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用
JP2014099344A Active JP5851550B2 (ja) 2008-05-09 2014-05-13 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014099344A Active JP5851550B2 (ja) 2008-05-09 2014-05-13 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用

Country Status (11)

Country Link
US (2) US8669225B2 (enExample)
EP (1) EP2285825B1 (enExample)
JP (2) JP5546532B2 (enExample)
KR (1) KR101616771B1 (enExample)
CN (1) CN102066399B (enExample)
AU (1) AU2009244742B2 (enExample)
BR (1) BRPI0908686B8 (enExample)
CA (1) CA2723563C (enExample)
IL (1) IL209155A (enExample)
RU (1) RU2010146684A (enExample)
WO (1) WO2009137112A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014177474A (ja) * 2008-05-09 2014-09-25 South Dakota State Univ 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
US20140234420A1 (en) * 2008-05-09 2014-08-21 Omathanu P. Perumal Method of Treating Skin Disorders using Nanoscale Delivery Devices and Transdermal Enhancing Compositions
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
CN102958384B (zh) 2010-06-30 2016-02-24 荷兰联合利华有限公司 包含疏水聚合物和疏水酚类化合物的颗粒
AU2011278186B2 (en) 2010-07-16 2015-02-05 Centro Nacional De Tecnologia Y Seguridad Alimentaria, Laboratorio Del Ebro Nanoparticles for the encapsulation of compounds, the obtaining and uses thereof
CN102120823B (zh) * 2011-01-06 2016-08-03 鲁传华 水溶性玉米朊的合成及在药物制剂中的运用
KR101952599B1 (ko) 2011-02-25 2019-05-22 사우스다코타주립대학 고분자 컨쥬게이트화된 단백질 마이셀
EP2678007A4 (en) * 2011-02-25 2015-08-12 Univ South Dakota PROTEIN NANOTRIER FOR TOPICAL ADMINISTRATION
AU2012225277A1 (en) * 2011-03-10 2013-09-26 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
CA2883080A1 (en) * 2011-08-26 2013-03-07 Vecoy Nanomedicines Ltd. Pathogen and substance traps
EP2625966A1 (en) 2012-02-13 2013-08-14 Bionanoplus, S.L. Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof
WO2014005299A1 (en) * 2012-07-04 2014-01-09 Empire Technology Development Llc Quantum dot-protein complexes, films, and methods of use
KR102045732B1 (ko) * 2012-12-28 2019-11-18 엘지디스플레이 주식회사 온도감응형 계면활성제를 이용한 수용성 나노입자의 제조방법
CN105682646A (zh) * 2013-06-04 2016-06-15 南达科他州立大学 用于口服药物递送的新型核-壳纳米颗粒
IL228528A (en) 2013-09-17 2015-01-29 Technion Res & Dev Foundation Potato-based nanoparticles
WO2016057799A1 (en) * 2014-10-09 2016-04-14 Therakine Use of meso-and nanoporous material for surfactant trapping in nanoparticle suspensions
WO2018071864A1 (en) 2016-10-13 2018-04-19 Thomas Jefferson University Delivery compositions, and methods of making and using same
CN110730656B (zh) * 2017-06-02 2022-09-16 特一华制药株式会社 水难溶性成分增溶胶束及含有该胶束的液体制剂
TWI642685B (zh) * 2017-07-26 2018-12-01 中原大學 新穎胜肽及其應用
CN109432433A (zh) * 2018-10-30 2019-03-08 中国药科大学 一种纳米载体的制备方法和用途
CN109730976B (zh) * 2018-12-24 2020-06-09 华中科技大学 一种基于自由基氧化制备白蛋白纳米粒的方法
CN110251487B (zh) * 2019-08-01 2021-11-02 郑州大学 一种提高多西他赛载药量和口服生物利用度的醇溶蛋白纳米粒的制备方法及其应用
CN112121019B (zh) * 2020-09-23 2022-05-31 合肥工业大学 抗氧化型淀粉基糊精复合纳米颗粒及其制备方法与应用
CN115025054B (zh) * 2022-06-09 2023-12-22 四川普锐特药业有限公司 一种以乳铁蛋白为载体的纳米组合物的制备方法
CN116998582A (zh) * 2023-08-08 2023-11-07 扬州大学 一种高溶解度油料植物蛋白的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2236521A (en) 1937-08-12 1941-04-01 Zein Corp Of America Ink
US5330778A (en) 1988-09-19 1994-07-19 Opta Food Ingredients, Inc. Hydrophobic protein microparticles
AU642932B2 (en) * 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5254673A (en) * 1991-12-26 1993-10-19 Opta Food Ingredients, Inc. Purification of zein from corn gluten meal
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
MY153295A (en) * 2004-09-29 2015-01-29 Nestec Sa Nanoparticulated whey proteins
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
KR20080111033A (ko) * 2006-03-29 2008-12-22 후지필름 가부시키가이샤 카제인 나노입자
EP2054036B1 (en) * 2006-07-24 2019-12-18 Singh-Broemer and Company, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
AU2009244742B2 (en) * 2008-05-09 2014-11-06 South Dakota State University Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor
EP2678007A4 (en) * 2011-02-25 2015-08-12 Univ South Dakota PROTEIN NANOTRIER FOR TOPICAL ADMINISTRATION

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014177474A (ja) * 2008-05-09 2014-09-25 South Dakota State Univ 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用

Also Published As

Publication number Publication date
US9616021B2 (en) 2017-04-11
HK1158221A1 (en) 2012-07-13
EP2285825A4 (en) 2012-11-28
CA2723563C (en) 2017-12-12
KR101616771B1 (ko) 2016-04-29
US8669225B2 (en) 2014-03-11
BRPI0908686B8 (pt) 2021-05-25
US20140308351A1 (en) 2014-10-16
AU2009244742B2 (en) 2014-11-06
AU2009244742A1 (en) 2009-11-12
IL209155A (en) 2016-07-31
CN102066399B (zh) 2014-11-26
WO2009137112A1 (en) 2009-11-12
KR20110036704A (ko) 2011-04-08
EP2285825A1 (en) 2011-02-23
IL209155A0 (en) 2011-01-31
RU2010146684A (ru) 2012-06-20
EP2285825B1 (en) 2020-07-15
CA2723563A1 (en) 2009-11-12
BRPI0908686B1 (pt) 2020-09-29
CN102066399A (zh) 2011-05-18
JP5851550B2 (ja) 2016-02-03
US20110091565A1 (en) 2011-04-21
JP2011519932A (ja) 2011-07-14
JP2014177474A (ja) 2014-09-25

Similar Documents

Publication Publication Date Title
JP5546532B2 (ja) 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用
Sailaja et al. Different techniques used for the preparation of nanoparticles using natural polymers and their application
JP7612247B2 (ja) 全細胞画分が担持された標的送達システム及びその使用
EP1752142B1 (en) Pegylated nanoparticles
JP2014515007A (ja) 局所送達のためのタンパク質ナノ担体
CN114288398B (zh) 基于全细胞组分的癌症疫苗系统在制备交叉预防或治疗异种癌症药物中的应用
Dobhal et al. Chitosan-Based nanoparticulate systems: Implication towards therapeutics application
Basu et al. Nanomaterials in Drug Delivery: Application of Polysaccharides and Protein-Based Nanomaterials in Modern Drug Delivery
Cismaru et al. Polymeric nanoparticles with biomedical applications
Shah et al. Strategies for Formulation and Systemic Delivery of Therapeutic Proteins
Rancan Biodegradable, biocompatible, and bioconjugate materials as delivery agents in dermatology: Safe drug delivery to skin
HK1158221B (en) Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor
JP5098225B2 (ja) 親水性活性物質含有微粒子の製造方法
Shah et al. chitosan Nanoparticles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110422

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20110422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140417

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140513

R150 Certificate of patent or registration of utility model

Ref document number: 5546532

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250